Makindo Medical Notes"One small step for man, one large step for Makindo" |
|
---|---|
Download all this content in the Apps now Android App and Apple iPhone/Pad App | |
MEDICAL DISCLAIMER: The contents are under continuing development and improvements and despite all efforts may contain errors of omission or fact. This is not to be used for the assessment, diagnosis, or management of patients. It should not be regarded as medical advice by healthcare workers or laypeople. It is for educational purposes only. Please adhere to your local protocols. Use the BNF for drug information. If you are unwell please seek urgent healthcare advice. If you do not accept this then please do not use the website. Makindo Ltd. |
Cause | Details |
---|---|
Mitral Valve Prolapse (MVP) | Mitral Valve Prolapse is the most common cause of MR in developed countries. It occurs when the mitral valve leaflets abnormally bulge (prolapse) back into the LA during systole, leading to incomplete closure of the valve and regurgitation of blood. |
Rheumatic Heart Disease | Rheumatic heart disease, post streptococcal throat infections, scarring and deformation of the mitral valve leaflets and chordae tendineae, leading to mitral regurgitation. Seen in developing countries. |
Ischaemic Heart Disease | IHD can lead to MR due to damage to the papillary muscles or left ventricular remodeling after a myocardial infarction. The papillary muscles, which anchor the mitral valve, may become dysfunctional or ruptured, leading to valve leakage. |
Endocarditis | Infective endocarditis damages the mitral valve leaflets or chordae tendineae, leading to acute or chronic MR. Can cause valve perforation, rupture of chordae, or the formation of vegetations that prevent proper valve closure. |
Degenerative Valve Disease | Degenerative changes in the mitral valve, such as annular dilation or calcification, can result in mitral regurgitation. These changes are often age-related and can lead to a weakened valve structure, causing incomplete closure during systole. |
Cardiomyopathy | Dilated or hypertrophic cardiomyopathy can cause mitral regurgitation due to the distortion of the mitral valve apparatus. In dilated cardiomyopathy, the enlargement of the left ventricle can lead to annular dilation, while in hypertrophic cardiomyopathy, abnormal septal motion can impair valve function. |
Congenital Mitral Valve Abnormalities | Some individuals are born with congenital defects that affect the mitral valve, such as cleft mitral valve or parachute mitral valve, leading to regurgitation. These abnormalities can cause improper valve closure from birth. |
Connective tissue disease | Marfan's disease, Osteogenesis imperfecta, Myxomatous degeneration. |
Trauma | Blunt chest trauma can cause acute mitral regurgitation by rupturing the chordae tendineae or papillary muscles, leading to a sudden onset of valve dysfunction. |
Management Strategy | Details |
---|---|
Medical Management |
Diuretics: ABC, Oxygen, IV Frusemide to treat LVF. Vasodilators: ACEi/ARBs reduce afterload and the regurgitant volume and improving cardiac output. Beta-blockers/Digoxin: Manages AF heart rate and reduce myocardial oxygen demand. Anticoagulation: Warfarin or DOAC or Heparin for Atrial fibrillation to prevent thromboembolism. |
Surgical Management |
Mitral Valve Repair: Preferred over replacement especially for degenerative mitral regurgitation. Annuloplasty, leaflet resection, or chordal replacement. Mitral Valve Replacement: when repair is not feasible. Replace with mechanical (metal) or bioprosthetic (tissue) valve. |
Percutaneous Mitral Valve Interventions |
MitraClip: A transcatheter procedure used in high-risk surgical candidates. The device clips the mitral valve leaflets together to reduce regurgitation. Transcatheter Mitral Valve Replacement (TMVR): An emerging option for patients who are not suitable candidates for surgery. |
Management of Atrial Fibrillation |
Rate Control: Beta-blockers, calcium channel blockers, or digoxin to control heart rate. Rhythm Control: Antiarrhythmic drugs or cardioversion to maintain sinus rhythm in selected patients. Anticoagulation: Essential to prevent thromboembolic events. |
Monitoring and Follow-up |
Echocardiography: Regular echocardiograms assess valve, left ventricular function, and pulmonary pressures. Clinical Assessment: Regular follow-ups, assess functional status, manage meds as needed. |
Lifestyle Modifications |
Exercise: Moderate exercise but avoid strenuous activities if symptomatic. Dietary Management: Sodium restriction reduce fluid retention and alleviate symptoms. Smoking Cessation: Smoking cessation is crucial for overall cardiovascular health. |